respiratori
symptom
sign
dyspnoea
cough
sputum
chest
pain
rale
haemoptysi
impair
oxygen
andor
pulmonari
infiltr
chest
radiograph
cxr
computer
tomographi
ct
scan
frequent
among
patient
haematolog
malign
hm
patient
undergo
chemotherapi
acut
leukaemia
may
affect
chaoui
et
al
garcia
et
al
particularli
preexist
pulmonari
diseas
smoke
around
sever
neutropen
patient
first
fever
present
lung
infiltr
li
maschmey
et
al
half
patient
without
abnorm
cxr
remain
febril
least
h
broadspectrum
antibacteri
treatment
show
li
pulmonari
ct
scan
heussel
et
al
respiratori
complic
also
frequent
among
patient
chronic
lymphocyt
leukaemia
often
run
complic
clinic
cours
due
complex
immunodefici
respiratori
event
affect
less
autolog
stem
cell
transplant
recipi
reich
et
al
howev
proport
may
high
particularli
among
patient
myeloma
experi
day
sever
neutropenia
substanti
associ
mortal
typic
public
caus
li
base
upon
clinic
data
imag
procedur
microbiolog
find
garcia
et
al
retrospect
analys
clinic
cours
patient
undergo
chemotherapi
acut
myeloid
leukaemia
aml
n
acut
lymphoblast
leukaemia
n
highrisk
myelodysplast
syndrom
md
n
undergo
chemotherapi
institut
found
pretreat
preval
pneumonia
occurr
pneumonia
overal
fatal
rate
cumul
incid
highest
among
patient
md
intermedi
aml
patient
patient
pneumonia
also
much
higher
overal
mortal
without
pneumonia
small
seri
patient
de
novo
secondari
acut
leukaemia
chaoui
et
al
identifi
respiratori
event
cardiac
failur
predomin
noninfecti
caus
aspergillosi
bacteri
pneumonia
due
gramneg
bacilli
main
caus
li
infecti
origin
major
occur
within
leukaemia
diagnosi
outcom
affect
patient
significantli
poorer
patient
without
chaoui
et
al
year
among
patient
chronic
lymphocyt
leukaemia
associ
poor
prognosi
fatal
rate
ahm
et
al
quarter
complic
caus
pneumonia
pleural
effus
lung
infiltr
underli
malign
pulmonari
leucostasi
secondari
malign
aggress
transform
richter
syndrom
bronchial
obstruct
respect
prognosi
granulocytopenia
renal
failur
unfavour
impact
clinic
outcom
histopatholog
find
avail
minor
case
may
show
varieti
differ
caus
li
includ
fungi
alveolar
bleed
infiltr
underli
malign
cryptogen
organ
pneumonia
immun
reconstitut
syndrom
lung
damag
chemotherapi
radiat
shorr
et
al
camu
costabel
druginduc
li
also
kept
mind
howev
small
number
chemotherapeut
agent
like
caus
li
among
febril
neutropen
patient
discuss
eg
alltran
retino
acid
atra
bcnu
carmustin
bleomycin
cyclophosphamid
highdos
cytosin
arabinosid
etoposid
gemcitabin
fludarabin
melphalan
methotrex
lung
infiltr
due
leucostasi
leukaem
infiltr
lung
newli
diagnos
acut
leukaemia
patient
present
fever
li
occasion
requir
immedi
intens
care
chaoui
et
al
darmon
et
al
patient
particularli
challeng
unclear
infiltr
due
pulmonari
involv
leukaemia
infect
result
underli
immunosuppress
koh
et
al
case
inform
lung
biopsi
autopsi
obtain
leukaem
infiltr
along
lymphat
peribronchovascular
septal
pleural
interstiti
tissu
repres
typic
pattern
koh
et
al
major
patient
affect
pulmonari
leucostasi
caus
hyperleucocytosi
potenza
et
al
acut
lysi
pneumopathi
associ
diffus
alveolar
damag
may
occur
shortli
follow
initi
cytotox
chemotherapi
tryka
et
al
differenti
syndrom
patient
acut
promyelocyt
leukaemia
apl
treat
alltran
retino
acid
atra
syndrom
address
detail
may
associ
fever
patient
typic
occur
set
fever
sever
neutropenia
luesink
jansen
primarili
induc
chemokin
releas
differenti
apl
cell
manag
antimicrobi
therapi
glucocorticosteroid
lung
infiltr
may
found
febril
neutropen
patient
convent
cxr
patient
first
fever
neutropenia
may
miss
li
pulmonari
ct
scan
obtain
circumst
probabl
show
li
larger
proport
patient
heussel
et
al
li
like
prove
fatal
compar
document
infect
febril
neutropen
patient
maschmey
et
al
treatment
complex
costli
kuder
et
al
garcia
et
al
clinic
outcom
deterior
increas
patient
age
particularli
dismal
patient
bacteraemia
shock
especi
appropri
antimicrobi
treatment
delay
carrat
et
al
favour
clinic
respons
antibacteri
treatment
achiev
less
patient
pulmonari
infiltr
febril
neutropenia
maschmey
et
al
raad
et
al
high
fatal
rate
al
ameri
et
al
addit
upfront
mouldact
system
antifung
amphotericin
b
voriconazol
increas
respons
rate
schiel
et
al
addit
find
indic
major
li
among
sever
neutropen
patient
caus
filament
fungi
particularli
aspergillu
spp
includ
reduct
incid
li
small
studi
voriconazol
prophylaxi
patient
acut
leukaemia
vehreschild
et
al
histopatholog
molecular
find
orl
et
al
autopsi
studi
chamilo
et
al
lung
infiltr
among
patient
treat
nucleosid
analogu
fludarabin
may
involv
rang
microorgan
cytomegaloviru
mycobacteria
yeast
typic
observ
prolong
cell
suppress
samoni
kontoyianni
well
staphylococcu
aureu
pseudomona
aeruginosa
aspergillu
spp
pneumococci
ahm
et
al
respiratori
virus
includ
influenza
respiratori
syncyti
viru
rsv
occasion
identifi
caus
pulmonari
infiltr
hospit
febril
neutropen
adult
martino
et
al
predominantli
wintertim
howev
least
febril
neutropenia
virolog
diagnost
test
seldom
order
uncertainti
relev
lack
effect
agent
treat
infect
vast
major
rsv
infect
occur
among
haematopoiet
stem
cell
transplant
recipi
report
viral
pneumonia
patient
mainli
involv
outpati
show
conflict
result
regard
clinic
import
lehner
et
al
human
metapneumoviru
hmpv
identifi
earli
affect
adult
patient
hm
symptom
respiratori
tract
infect
william
et
al
outcom
tend
favour
despit
absenc
effect
antihmpv
antivir
godet
et
al
howev
recent
outbreak
pulmonari
hmpv
infect
among
haematolog
patient
associ
fatal
rate
patient
hoellein
et
al
convent
cxr
show
abnorm
less
febril
neutropen
patient
obviou
clinic
sign
symptom
lower
respiratori
tract
infect
navigant
et
al
oud
nijhui
et
al
unreason
assum
mani
patient
would
abnorm
detect
ct
scan
prospect
random
studi
compar
yield
ct
scan
versu
cxr
conduct
howev
among
neutropen
patient
fever
persist
despit
h
broadspectrum
antibacteri
therapi
cxr
show
abnorm
highresolut
ct
scan
taken
time
show
patholog
find
approxim
patient
heussel
et
al
abnorm
seen
cxr
indic
ct
scan
done
specif
identifi
like
aetiolog
henc
cxr
limit
valu
pulmonari
ct
scan
without
contrast
media
must
order
anyway
soon
possibl
prefer
part
investig
fever
neutropenia
pattern
lung
infiltr
pulmonari
ct
scan
inform
differenti
diagnosi
detect
li
ct
scan
three
prognost
import
consequ
earli
detect
lesion
indic
invas
mould
diseas
pneumocysti
pneumonia
pcp
facilit
target
bronchoalveolar
lavag
bal
prompt
institut
preemptiv
antimicrobi
treatment
result
improv
surviv
patient
guo
et
al
ct
find
consolid
small
nodul
without
typic
revers
halo
sign
aircresc
sign
may
import
sign
filament
fungal
diseas
halo
sign
ie
dens
nodular
infiltr
surround
area
groundglass
opac
repres
infarct
haemorrhag
describ
characterist
neutropen
patient
invas
pulmonari
aspergillosi
ipa
bruno
et
al
revers
halo
sign
show
focal
round
area
groundglass
opac
surround
crescent
complet
ring
consolid
report
rel
specif
fungal
pneumonia
due
mucormycosi
georgiad
et
al
legoug
et
al
howev
also
may
also
associ
lung
diseas
tuberculosi
sarcoidosi
cryptogen
organ
pneumonia
godoy
et
al
pattern
li
ct
scan
may
also
help
distinguish
fungal
aetiolog
li
caillot
et
al
heussel
et
al
pcp
typic
caus
diffus
perihilar
infiltr
area
groundglass
attenu
cyst
septal
thicken
consolid
centrilobular
nodul
kann
et
al
vogel
et
al
howev
classic
pcp
pattern
also
describ
li
acut
leukaemia
potenza
et
al
nodular
cavitari
lesion
indic
invas
mould
diseas
differenti
diagnos
includ
pneumonia
caus
microorgan
mycobacteria
patient
high
preval
area
nocardia
pneumocysti
jirovecii
pseudomona
aeruginosa
infiltr
underli
malign
shorr
et
al
combin
ct
scan
angiographi
report
increas
diagnost
specif
case
suspect
pulmonari
mould
diseas
stanzani
et
al
vessel
occlus
better
seen
nativ
scan
howev
procedur
labourintens
also
burdensom
patient
due
use
contrast
media
ad
valu
ct
find
yet
establish
magnet
reson
tomographi
mri
may
altern
ct
scan
appear
inferior
ct
visual
groundglass
opac
attenberg
et
al
followup
ct
scan
usual
order
least
elaps
start
antimicrobi
therapi
otherwis
cours
li
may
misinterpret
patient
invas
pulmonari
aspergillosi
may
show
increas
li
volum
first
week
despit
effect
antifung
therapi
caillot
et
al
may
creat
fals
impress
current
antifung
medic
ineffect
chang
regress
halo
sign
appear
aircresc
sign
howev
usual
indic
favour
respons
brodoefel
et
al
make
microbiolog
diagnosi
use
order
prompt
bronchoscopi
ical
document
case
frequent
base
upon
find
bronchial
secret
bal
fluid
even
blood
cultur
obtain
contemporan
diagnost
relev
cultur
result
howev
often
difficult
assess
boersma
et
al
azoulay
et
al
bronchial
sampl
patient
may
contain
microorgan
aetiolog
signific
candida
speci
coagulaseneg
staphylococci
viridan
streptococci
enterococci
moreov
bacteraemia
due
bacteria
seldom
ever
result
pneumonia
time
mani
case
invas
fungal
diseas
found
autopsi
detect
ant
mortem
chamilo
et
al
contrast
isol
aspergillu
spp
filament
fungi
oropharyng
upper
respiratori
tract
specimen
sever
immunocompromis
patient
regard
sign
pulmonari
mould
infect
perfect
et
al
import
bronchoscopi
bal
among
febril
neutropen
patient
li
controversi
diagnost
yield
low
clinic
outcom
patient
yet
shown
improv
invas
diagnost
procedur
includ
bal
azoulay
et
al
howev
detect
rate
report
potenti
pathogen
bal
sampl
patient
cancer
jain
et
al
boersma
et
al
bacteria
account
third
p
jirovecii
among
patient
receiv
cotrimoxazol
prophylaxi
filament
fungi
predominantli
aspergillu
spp
diagnost
gold
standard
biopsi
seldom
justifi
imposs
estim
number
falseposit
falseneg
find
bal
sampl
benefit
failur
pathogendirect
antimicrobi
treatment
therefor
remain
obscur
list
microorgan
gener
regard
irrelev
aetiolog
li
given
tabl
noncultur
base
diagnost
method
antigen
detect
polymeras
chain
reaction
help
respiratori
virus
may
caus
li
among
patient
profound
cellular
immunosuppress
bal
nasopharyng
oral
swab
includ
investig
cmv
influenza
parainfluenza
rsv
coronaviru
rhinoviru
hmpv
william
et
al
hirsch
et
al
cmv
polymeras
chain
reaction
pcr
recommend
bal
sampl
febril
neutropen
patient
li
test
high
neg
predict
valu
cmv
exclud
howev
posit
predict
valu
low
hohenth
et
al
rapid
cultur
immedi
earli
antigen
direct
fluoresc
antibodi
test
dna
hybrid
cytolog
requir
confirm
diagnosi
cmv
pneumonia
boeckh
microscopi
classic
refer
method
detect
p
jirovecii
larg
replac
pcr
earli
detect
exhibit
high
sensit
essenti
distinguish
infect
colon
may
affect
half
individu
without
sign
symptom
pcp
ponc
et
al
metaanalysi
pcr
show
test
exhibit
high
sensit
specif
lu
et
al
henc
neg
test
result
bal
sampl
indic
antipneumocysti
therapi
unnecessari
recent
quantit
pcr
assay
shown
boost
specif
report
nonhiv
patient
proven
pcp
show
posit
predict
valu
organ
per
ml
detect
bal
sampl
uhlethal
et
al
howev
threshold
yet
prospect
evalu
clinic
studi
individu
patient
sever
pcp
much
lower
copi
number
may
present
determin
betadglucan
serum
also
help
differenti
diagnosi
neg
result
effect
rule
diagnosi
pcp
karageorgopoulo
et
al
numer
method
develop
detect
fungal
cell
antigen
aspergillu
galactomannan
gm
nuclear
amplif
assay
includ
pcr
identifi
fungal
dna
earli
detect
filament
fungi
febril
neutropen
patient
li
undetermin
aetiolog
maerten
et
al
spiess
et
al
current
optic
densiti
od
index
blood
sampl
regard
threshold
detect
gm
wherea
cutoff
appropri
bal
sampl
zou
et
al
indic
probabl
invas
fungal
diseas
sever
immunocompromis
patient
whether
aspergillu
gm
detect
blood
earlier
find
suggest
infiltr
chest
ct
scan
contenti
weisser
et
al
gm
test
also
prone
yield
falseposit
result
blood
sampl
obtain
patient
treat
semisynthet
betalactam
antibiot
amoxicillinclavulan
piperacillintazobactam
carbapenem
ceftriaxon
cefepim
boonsarngsuk
et
al
given
enter
nutrit
girmenia
et
al
fungal
infect
fusariosi
tortorano
et
al
falseposit
gm
also
found
bal
sampl
obtain
use
specif
lavag
solut
plasmalyt
tm
hage
et
al
may
also
due
blood
product
mart
et
al
system
antifung
prophylaxi
mouldact
azol
posaconazol
also
reduc
reliabl
aspergillu
gm
test
duart
et
al
signific
declin
gm
od
indic
note
result
storag
serum
sampl
bal
sampl
time
take
blood
sampl
test
minim
detail
antigen
test
fungal
infect
aspergillosi
review
elsewher
ruhnk
et
al
studi
panfung
aspergillusspecif
pcr
assay
indic
bal
sampl
may
superior
blood
sampl
particularli
patient
receiv
system
antifung
therapi
spiess
et
al
musher
et
al
pcr
also
appear
use
lung
biopsi
specimen
addit
histopatholog
cultur
allow
identif
pathogen
rickert
et
al
lack
standard
pcr
blood
bal
sampl
primari
reason
incorpor
assay
european
organ
research
treatment
cancer
eortc
mycos
studi
group
msg
definit
invas
fungal
diseas
howev
progress
made
european
aspergillu
pcr
initi
http
wwweapcrieu
cogent
argument
recent
publish
includ
pcr
eortcmsg
definit
white
et
al
also
seem
like
pcr
incorpor
diagnost
workup
li
alongsid
thorac
ct
scan
serolog
convent
microbiolog
blood
bal
sampl
white
et
al
combin
aspergillu
pcr
gm
bal
sampl
enhanc
diagnosi
detect
gm
pcr
make
diagnosi
pulmonari
aspergillosi
highli
like
confirm
metaanalys
avni
et
al
nonetheless
previou
exposur
antifung
therapi
may
reduc
sensit
quantit
pcr
assay
well
aspergillu
gm
test
mcculloch
et
al
nosocomi
legionellosi
among
patient
cancer
fortun
rare
though
singl
centr
report
recommend
test
legionella
includ
differenti
diagnosi
gudiol
et
al
test
urin
legionella
pneumophila
serogroup
antigen
help
make
rapid
diagnosi
proper
clinic
studi
support
routin
test
reli
biomark
creactiv
protein
procalcitonin
interleukin
proinflammatori
serum
marker
creactiv
protein
crp
interleukin
interleukin
tumour
necrosi
factoralpha
procalcitonin
robinson
et
al
evalu
result
heterogen
make
valid
conclus
imposs
marker
yet
studi
prospect
febril
neutropen
patient
li
clinic
practic
serial
measur
crp
typic
parallel
clinic
cours
infect
use
guid
therapeut
decis
togeth
clinic
imag
find
persist
fever
progress
newli
emerg
li
rise
proinflammatori
paramet
typic
indic
need
chang
antimicrobi
treatment
regimen
robinson
et
al
procalcitonin
use
neg
predict
valu
repeat
failur
detect
biomark
context
li
fever
high
inflammatori
marker
crp
despit
broadspectrum
antimicrobi
treatment
suggest
infiltr
may
due
underli
haematolog
malign
therefor
reason
start
chemotherapi
bele
et
al
algorithm
clinic
manag
febril
neutropen
patient
li
propos
recent
guidelin
infecti
diseas
work
parti
german
societi
haematolog
medic
oncolog
maschmey
et
al
figur
depict
clinic
pathway
reflect
recommend
patient
aml
md
undergo
aggress
myelosuppress
chemotherapi
expect
sever
neutropenia
last
serial
monitor
aspergillu
gm
blood
sampl
recommend
patient
fever
unknown
origin
respond
empir
firstlin
therapi
antipseudomon
betalactam
antibiot
h
undergo
thorough
physic
reexamin
imag
microbiolog
diagnost
includ
mostli
nativ
ie
without
contrast
media
thorac
ct
scan
li
present
andor
aspergillu
gm
posit
noninvas
diagnost
test
repeat
bronchoscopi
bal
use
standard
protocol
sampsona
et
al
arrang
within
maximum
h
microbiolog
tabl
ii
addit
assay
may
ad
eg
molecular
test
respiratori
virus
individu
case
pneumonia
acquir
hospit
invas
procedur
open
lung
percutan
core
needl
biopsi
consid
patient
undetermin
li
urgent
requir
histolog
identif
bronchoscopi
bal
fail
consid
dismal
prognosi
febril
neutropen
patient
li
treat
promptli
appropri
antimicrobi
regimen
recommend
start
therapi
basi
clinic
imag
andor
laboratori
find
indic
particular
infect
patient
risk
without
proof
infect
type
underli
malign
immunosuppress
instrument
impact
select
antimicrobi
agent
suitabl
system
therapi
patient
without
conclus
microbiolog
find
lack
respons
antimicrobi
treatment
reassess
includ
thorac
ct
scan
eventu
also
bronchoscopi
bal
arrang
clinic
outcom
proven
invas
mould
infect
aspergillosi
mucormycosi
neutropen
patient
poor
lin
et
al
earli
mouldact
antifung
treatment
ad
broadspectrum
antipseudomon
betalactam
patient
whose
li
typic
radiolog
pattern
pcp
lobar
bacteri
pneumonia
maschmey
et
al
shown
patient
invas
aspergillosi
treat
voriconazol
liposom
amphotericin
b
superior
respons
surviv
rate
treat
earli
vs
later
cours
diseas
patient
pretreat
voriconazol
posaconazol
system
antifung
prophylaxi
breakthrough
filament
fungal
pneumonia
presum
antifung
drug
level
check
invas
diagnost
procedur
taken
consider
antifung
treatment
switch
liposom
amphotericin
b
patient
thorac
ct
scan
suggest
pcp
rapid
otherwis
unexplain
rise
serum
lactat
dehydrogenas
prompt
start
highdos
cotrimoxazol
recommend
see
bal
remain
posit
pjirovecii
sever
day
despit
appropri
antimicrobi
therapi
roger
et
al
recommend
howev
valid
patient
receiv
antipneumocysti
prophylaxi
group
patient
antivir
agent
glycopeptid
fluoroquinolon
macrolid
antibiot
routin
given
without
convinc
diagnosi
clinic
signific
sampl
patient
undergo
highdos
chemotherapi
ahsct
low
risk
fungal
pneumonia
post
et
al
therefor
earli
antifung
therapi
recommend
myeloma
patient
pretreat
bortezomib
total
bodi
irradi
alemtuzumab
antithymocyt
globulin
fludarabin
use
condit
cmv
diseas
may
consid
fassa
et
al
ljungman
et
al
marchesi
et
al
bal
check
pathogen
posit
rapid
cultur
immedi
earli
antigen
prompt
antivir
treatment
konoplev
et
al
importantli
quantit
measur
cmv
copi
blood
sampl
correl
risk
cmv
pneumonia
ng
et
al
firstchoic
antivir
treatment
option
foscarnet
ganciclovir
latter
may
caus
critic
myelosuppress
revers
nephrotox
typic
side
effect
foscarnet
antimicrobi
treatment
pneumonia
caus
bacteria
typic
suscept
standard
broadspectrum
betalactam
antibiot
must
individu
apart
critic
discuss
caus
role
pathogen
isol
diagnost
sampl
see
vitro
suscept
pattern
pharmacokinet
aspect
penetr
lung
tissu
possibl
inactiv
surfact
must
alway
includ
select
patient
multiresist
gramneg
pathogen
aerosol
colistin
success
use
part
antimicrobi
strategi
stenotrophomona
maltophilia
rare
caus
pneumonia
haematolog
patient
frequent
associ
blood
stream
infect
case
infect
venou
access
treatment
recommend
select
bacteri
pneumonia
list
tabl
iii
aspergillu
speci
mucoral
typic
pathogen
fungi
caus
li
sever
neutropen
patient
candida
spp
frequent
isol
respiratori
tract
sampl
repres
caus
li
rare
case
dissemin
candida
fungaemia
haematogen
spread
lung
kontoyianni
et
al
updat
recommend
treatment
document
mucormycosi
provid
evidencebas
guidelin
mousset
et
al
corn
et
al
schelenz
et
al
firstlin
treatment
invas
pulmonari
aspergillosi
intraven
voriconazol
mgkg
everi
h
day
mgkg
everi
h
thereaft
liposom
amphotericin
b
mgkgd
mucormycosi
zygomycosi
liposom
amphotericin
b
dose
mgkgd
prefer
patient
need
fulldos
antifung
therapi
show
clinic
improv
defervesc
decreas
inflammatori
paramet
declin
dyspnoea
better
oxygen
wherea
ct
scan
taken
first
week
treatment
often
show
increas
volum
li
caillot
et
al
antifung
treatment
chang
point
unless
new
li
emerg
previous
normal
pulmonari
site
clinic
deterior
obviou
second
infect
immun
reconstitut
syndrom
infiltr
caus
underli
malign
toxic
side
effect
cancer
treatment
revisit
segal
et
al
pcp
suspect
treatment
cotrimoxazol
trimethoprimsulfamethoxazol
tmpsmx
dosag
tmp
mgkg
plu
smx
mgkgd
initi
bal
induc
sputum
sampl
obtain
treatment
delay
may
enhanc
mortal
guo
et
al
blood
ga
analysi
done
start
antimicrobi
therapi
oxygen
partial
pressur
mm
hg
alveolararteri
oxygen
differ
mm
hg
upfront
oral
smego
et
al
potenti
salvag
regimen
includ
atovaquon
oral
suspens
mg
twice
daili
oral
meal
intraven
pentamidin
mgkgd
subsequ
patient
given
secondari
prophylaxi
tmpsmx
mg
given
oral
per
week
monthli
pentamidin
inhal
dose
mg
patient
respiratori
failur
use
system
corticosteroid
controversi
recent
nonrandom
studi
show
clinic
benefit
moon
et
al
associ
increas
mortal
lemial
et
al
clear
benefit
adjunct
administr
granulocyt
colonystimul
factor
gcsf
granulocytemacrophag
colonystimul
factor
longer
avail
european
countri
term
respons
surviv
rate
demonstr
henc
use
drug
recommend
inde
report
pulmonari
function
deterior
treatment
gcsf
karlin
et
al
refer
leukaemia
patient
acut
respiratori
failur
intens
care
unit
contrast
widespread
opinion
neutropen
patient
respiratori
failur
may
favour
outcom
appropri
intens
care
includ
mechan
ventil
maschmey
et
al
even
invas
aspergillosi
identifi
underli
complic
particular
problem
aris
patient
whose
clinic
condit
deterior
due
haematopoiet
recoveri
may
happen
onethird
patient
li
emerg
neutropenia
especi
acut
leukaemia
previou
sever
neutropenia
last
result
acut
respiratori
distress
syndrom
import
misinterpret
worsen
failur
antimicrobi
therapi
consequ
switch
irrat
antimicrobi
polypharmacotherapi
drug
combin
rather
optim
support
care
tri
lead
patient
critic
period
immun
recoveri
long
antimicrobi
treatment
continu
spars
data
durat
antimicrobi
treatment
patient
li
respond
treatment
decis
durat
treatment
influenc
natur
pneumonia
result
interim
respons
assess
patient
pcp
week
recommend
see
bacteri
pneumonia
resolut
clinic
laboratori
sign
activ
infect
document
typic
treatment
cmv
pneumonia
week
treatment
appear
suffici
respect
high
risk
relaps
patient
invas
pulmonari
mould
infect
receiv
system
antifung
treatment
haematopoiet
recoveri
regress
clinic
radiolog
sign
infect
